Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment | AHRQ Effective Health Care Program

Comment on Key Questions
Please fill out the form below to provide comments on the key questions associated with this topic.Draft Key Questions:


Before you get started

1.PLEASE NOTE: Most text-entry areas on this form have an 8,000-character limit.

2.If you prefer, you can prepare your comments in an electronic document (*.doc, *.xls, and *.pdf) and upload it using the function below, or mail it to the address below. Comments submitted in writing will be handled in the same manner as those submitted online, including application of the privacy policy.

Scientific Resource Center, Oregon EPC
Mail code: BICC
3181 S.W. Sam Jackson Park Road
Portland, Oregon 97239-3098

Proposed Research Title for the Topic:
Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
Open for comment until 11:59 P.M. eastern time on Aug. 23, 2011.

These questions are available for public comment from July 26–Aug. 23, 2011
Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment
open here please>>>
Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment AHRQ Effective Health Care Program